We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
BRAF mutation in papillary thyroid carcinoma.
- Authors
Cohen, Yoram; Mingzhao Xing; Mambo, Elizabeth; Zhongmin Guo; Guogun Wu; Trink, Barry; Beller, Uziel; Westra, William H.; Ladenson, Paul W.; Sidransky, David; Xing, Mingzhao; Guo, Zhongmin; Wu, Guogun
- Abstract
The BRAF gene has been found to be activated by mutation in human cancers, predominantly in malignant melanoma. We tested 476 primary tumors, including 214 lung, 126 head and neck, 54 thyroid, 27 bladder, 38 cervical, and 17 prostate cancers, for the BRAF T1796A mutation by polymerase chain reaction (PCR)-restriction enzyme analysis of BRAF exon 15. In 24 (69%) of the 35 papillary thyroid carcinomas examined, we found a missense thymine (T)-->adenine (A) transversion at nucleotide 1796 in the BRAF gene (T1796A). The T1796A mutation was detected in four lung cancers and in six head and neck cancers but not in bladder, cervical, or prostate cancers. Our data suggest that activating BRAF mutations may be an important event in the development of papillary thyroid cancer.
- Subjects
CANCER genetics; GENETIC mutation; HEAD tumors; HETEROCYCLIC compounds; LUNG tumors; NECK tumors; POLYMERASE chain reaction; PURINES; THYROID gland tumors; TRANSFERASES; CASE-control method; PAPILLARY carcinoma; CANCER cell culture
- Publication
JNCI: Journal of the National Cancer Institute, 2003, Vol 95, Issue 8, p625
- ISSN
0027-8874
- Publication type
journal article
- DOI
10.1093/jnci/95.8.625